{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:49:29Z","timestamp":1792154969854,"version":"4.4.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Small cell lung cancer (SCLC) is an aggressive malignant tumor that mainly originates from pulmonary neuroendocrine cells and is characterized by rapid proliferation, high metastatic potential, and acquired therapeutic resistance. The therapeutic landscape for SCLC is largely confined to traditional modalities, such as surgery and chemoradiotherapy. However, 80\u201385% of patients are diagnosed with extensive-stage SCLC at initial presentation; surgical intervention and radiotherapy are often not applicable for these patients. Despite the initial favorable response of SCLC to chemotherapy, most patients develop resistance and experience rapid disease recurrence, leading to a poor prognosis. Historically, radiotherapy was the main mode of first-line treatment. With the advent of immune checkpoint inhibitors (ICIs) in recent years, the field of oncology has witnessed new therapeutic modalities and strategies. The combination of immunotherapy and chemotherapy has led to the development of extremely effective strategies for treating SCLC, significantly extending overall survival for a subset of patients. However, the overall clinical benefit remains limited; therefore, further optimization needs to be performed. This need has encouraged researchers to investigate novel therapeutic strategies. Antibody\u2013drug conjugates targeting antigens, such as DLL3, B7-H3, and TROP2, are extremely effective in treating relapsed\/refractory SCLC. In this review, the latest research advances in the carcinogenic, invasive, and drug-resistance mechanisms of SCLC have been summarized. We focused on the progress in the treatment modalities for SCLC and discussed future perspectives involving novel therapeutic combinations, assessment of new targets, and strategies to overcome treatment resistance.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_343_26","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:00:30Z","timestamp":1787817630000},"page":"623-632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Advances and future perspectives in the treatment of small cell lung cancer: From chemotherapy and radiotherapy to the era of targeted therapy and immunotherapy"],"prefix":"10.4103","volume":"22","author":[{"given":"Xiangwei","family":"Cheng","sequence":"first","affiliation":[{"name":"School of Graduate Studies, Wannan Medical College, Wuhu, China"},{"name":"Department of Oncology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Lv","sequence":"additional","affiliation":[{"name":"School of Graduate Studies, Wannan Medical College, Wuhu, China"},{"name":"Department of Oncology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Graduate Studies, Wannan Medical College, Wuhu, China"},{"name":"Department of Oncology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Graduate Studies, Wannan Medical College, Wuhu, China"},{"name":"Department of Oncology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"R1-20261016","first-page":"620","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10388-011-0267-7","article-title":"Chemotherapy-induced toxicities and treatment efficacy in advanced esophageal cancer treated with neoadjuvant chemotherapy followed by surgery","volume":"8","author":"Motoori","year":"2011","journal-title":"Esophagus"},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41392-025-02153-7","article-title":"Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A multicenter, single-arm trial","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R4-20261016","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1097\/JTO.0000000000000250","article-title":"Therapeutic priority of the PI3K\/AKT\/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis","volume":"9","author":"Umemura","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"R6-20261016","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jtho.2023.07.012","article-title":"Lineage plasticity in SCLC generates non-neuroendocrine cells primed for vasculogenic mimicry","volume":"18","author":"Pearsall","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R7-20261016","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1038\/s41467-023-41585-z","article-title":"YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis","volume":"14","author":"Zhengming","year":"2023","journal-title":"Nat Commun"},{"key":"R8-20261016","doi-asserted-by":"crossref","first-page":"e166402","DOI":"10.1172\/jci.insight.166402","article-title":"Blocking the angiopoietin-2-dependent integrin \u03b2-1 signaling axis abrogates small cell lung cancer invasion and metastasis","volume":"9","author":"Meder","year":"2024","journal-title":"JCI Insight"},{"key":"R9-20261016","first-page":"1","article-title":"IL20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer","volume":"132","author":"Yunfei","year":"2022","journal-title":"J Clin Invest"},{"key":"R10-20261016","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41556-023-01241-6","article-title":"Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis","volume":"25","author":"Qu","year":"2023","journal-title":"Nat Cell Biol"},{"key":"R11-20261016","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s43018-022-00361-6","article-title":"KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming","volume":"3","author":"Feifei","year":"2022","journal-title":"Nat Cancer"},{"key":"R12-20261016","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Shuncong","year":"2017","journal-title":"Sci Rep"},{"key":"R13-20261016","doi-asserted-by":"crossref","first-page":"100059","DOI":"10.1016\/j.esmoop.2021.100059","article-title":"Small-cell lung cancer in never-smokers","volume":"6","author":"Torres-Dur\u00e1n","year":"2021","journal-title":"ESMO Open"},{"key":"R14-20261016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Masahiko","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"R15-20261016","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1038\/s41467-026-69262-x","article-title":"Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC","volume":"17","author":"Chakraborty","year":"2026","journal-title":"Nat Commun"},{"key":"R16-20261016","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1101\/gad.340133.120","article-title":"MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity","volume":"34","author":"Grunblatt","year":"2020","journal-title":"Genes Dev"},{"key":"R17-20261016","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","article-title":"Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade","volume":"42","author":"Nabet","year":"2024","journal-title":"Cancer Cell"},{"key":"R18-20261016","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12672-023-00793-1","article-title":"Regulation of T cells by myeloid-derived suppressor cells: Emerging immunosuppressor in lung cancer","volume":"14","author":"He","year":"2023","journal-title":"Discov Oncol"},{"key":"R19-20261016","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.trecan.2024.07.008","article-title":"Small cell lung cancer profiling: An updated synthesis of subtypes, vulnerabilities, and plasticity","volume":"10","author":"Redin","year":"2024","journal-title":"Trends Cancer"},{"key":"R20-20261016","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s43018-019-0020-z","article-title":"Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer","volume":"1","author":"Stewart","year":"2020","journal-title":"Nat Cancer"},{"key":"R21-20261016","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2018.06.023","article-title":"The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes","volume":"101","author":"Bonanno","year":"2018","journal-title":"Eur J Cancer"},{"key":"R22-20261016","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-025-01690-6","article-title":"Current and future therapies for small cell lung carcinoma","volume":"18","author":"Zhai","year":"2025","journal-title":"J Hematol Oncol"},{"key":"R23-20261016","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1200\/JCO.1990.8.1.33","article-title":"Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: A randomized trial of the North Central Cancer Treatment Group","volume":"8","author":"Jett","year":"1990","journal-title":"J Clin Oncol"},{"key":"R24-20261016","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","article-title":"Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group","volume":"10","author":"Roth","year":"1992","journal-title":"J Clin Oncol"},{"key":"R25-20261016","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"R26-20261016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"R27-20261016","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): A randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"R28-20261016","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4103\/jcrt.jcrt_1171_25","article-title":"Hepatic artery infusion chemotherapy for liver metastases in small cell lung cancer","volume":"21","author":"Deng","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R29-20261016","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Rd","year":"1999","journal-title":"N Engl J Med"},{"issue":"(Sup 3)","key":"R30-20261016","doi-asserted-by":"crossref","first-page":"102766","DOI":"10.1016\/j.esmoop.2024.102766","article-title":"193O Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: A brief report from the CONVERT trial","volume":"9","author":"Walls","year":"2024","journal-title":"ESMO Open"},{"key":"R31-20261016","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: A phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"R32-20261016","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2025.06.3872","article-title":"Low-dose radiation therapy concurrent with atezolizumab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer: 3-year follow-up of a multicenter, single-arm, phase 2 trial (MATCH)","volume":"124","author":"Zhou","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R33-20261016","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4103\/jcrt.jcrt_251_25","article-title":"Precision treatment patterns and prognostic analysis: A retrospective study of small-cell lung cancer","volume":"21","author":"Wang","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R34-20261016","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: A multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"R35-20261016","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Leora","year":"2018","journal-title":"N Engl J Med"},{"key":"R36-20261016","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"R37-20261016","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4103\/jcrt.jcrt_500_24","article-title":"Clinical features and prognosis analysis of stage III\/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective","volume":"20","author":"Wang","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R38-20261016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","article-title":"Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy-results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"R39-20261016","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"R40-20261016","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"R41-20261016","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"R42-20261016","doi-asserted-by":"crossref","first-page":"e70351","DOI":"10.1002\/cncr.70351","article-title":"Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial","volume":"132","author":"Song","year":"2026","journal-title":"Cancer"},{"key":"R43-20261016","doi-asserted-by":"crossref","first-page":"109376","DOI":"10.1016\/j.lungcan.2026.109376","article-title":"Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level differences","volume":"215","author":"Lamberti","year":"2026","journal-title":"Lung Cancer"},{"key":"R44-20261016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R45-20261016","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/cas.13997","article-title":"DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail","volume":"110","author":"Megumi","year":"2019","journal-title":"Cancer Sci"},{"key":"R46-20261016","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41416-023-02427-3","article-title":"Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer","volume":"129","author":"Masayuki","year":"2023","journal-title":"Br J Cancer"},{"key":"R47-20261016","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R48-20261016","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1080\/14796694.2024.2402152","article-title":"Plain language summary: Tarlatamab for patients with previously treated small cell lung cancer","volume":"20","author":"Ahn","year":"2024","journal-title":"Future Oncol"},{"key":"R49-20261016","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/2326-6066.CIR-23-0638","article-title":"Engineering CD3\/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small-cell lung cancer","volume":"12","author":"Mikami","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"R50-20261016","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: Results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R51-20261016","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-High SCLC: Results from the phase 3 TAHOE study","volume":"16","author":"Fiona","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R52-20261016","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: Primary analysis of the phase II IDeate-Lung01 Trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol"},{"key":"R53-20261016","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccell.2026.02.006","article-title":"HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a\/b trial","volume":"44","author":"Duan","year":"2026","journal-title":"Cancer Cell"},{"issue":"(10S)","key":"R54-20261016","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jtho.2024.09.034","article-title":"OA04.04 sacituzumab govitecan as second-line treatment in patients with extensive stage small cell lung cancer","volume":"19","author":"Dowlati","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R55-20261016","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"issue":"(11S)","key":"R56-20261016","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.jtho.2023.09.250","article-title":"MA18.09 Carboplatin, Etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC-GOIRC-01-2019 CeLEBrATE trial","volume":"18","author":"Lamberti","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R57-20261016","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","article-title":"Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: A randomised, double-blind, placebo-controlled Phase 2 study","volume":"125","author":"Cheng","year":"2021","journal-title":"Br J Cancer"},{"key":"R58-20261016","doi-asserted-by":"crossref","first-page":"e052556","DOI":"10.1136\/bmjopen-2021-052556","article-title":"Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: A retrospective cohort study","volume":"13","author":"Blackhall","year":"2023","journal-title":"BMJ Open"},{"key":"R59-20261016","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.21037\/tlcr-2025-490","article-title":"Surgical treatment of small-cell lung cancer: Long-term prognosis and patterns of adjuvant therapy","volume":"14","author":"Cui","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"R60-20261016","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"R61-20261016","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: Results from TROPiCS-03","volume":"20","author":"Dowlati","year":"2025","journal-title":"J Thorac Oncol"},{"key":"R62-20261016","doi-asserted-by":"crossref","first-page":"15330338251329248","DOI":"10.1177\/15330338251329248","article-title":"Combining immunotherapy with anlotinib in extensive-stage small cell lung cancer: A multicenter analysis of efficacy and safety","volume":"24","author":"Gao","year":"2025","journal-title":"Technol Cancer Res Treat"},{"key":"R63-20261016","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: A randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nat Med"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_343_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:01:24Z","timestamp":1792152084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_343_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_343_26","relation":{},"ISSN":["1998-4138","0973-1482"],"issn-type":[{"value":"1998-4138","type":"print"},{"value":"0973-1482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"2026-03-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}